Investors fret as VBI's hep B vaccine fails key secondary PhIII study goal
Sobered by mounting costs, Dynavax $DVAX last month made the decision to focus all its resources on its 2017-approved hepatitis B vaccine Heplisav-B, which rivals and supersedes the efficacy and convenience profile of GSK’s $GSK established Engerix-B. The California-based company will be on the lookout for another competitor — VBI Vaccines, which on Monday unveiled late-stage data on its hep B vaccine: Sci-B-Vac.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.